These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9410098)

  • 21. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
    Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
    Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group.
    Clin Investig; 1994 Jan; 72(2):111-6. PubMed ID: 8186655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
    Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
    Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
    Infection; 1996; 24(6):419-25. PubMed ID: 9007588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.
    Montaner JS; Singer J; Schechter MT; Raboud JM; Tsoukas C; O'Shaughnessy M; Ruedy J; Nagai K; Salomon H; Spira B
    AIDS; 1993 Feb; 7(2):189-96. PubMed ID: 8466681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
    Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
    Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
    Carr A; Vella S; de Jong MD; Sorice F; Imrie A; Boucher CA; Cooper DA
    AIDS; 1996 Jun; 10(6):635-41. PubMed ID: 8780818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment.
    Maehlen J; Dunlop O; Liestøl K; Dobloug JH; Goplen AK; Torvik A
    AIDS; 1995 Oct; 9(10):1165-9. PubMed ID: 8519453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.
    Angarano G; Monno L; Vivirito MC; Appice A; Romanelli C; Giannelli A; La Grasta L; Fracasso C; Fiore JR; Milazzo F
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):969-75. PubMed ID: 8827212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of serum adenosine deaminase as a prognostic marker in the treatment of human immunodeficiency virus infection with zidovudine].
    Carrera J; Porras JA; Vidal F; Pinto B; Richart C
    Rev Clin Esp; 1995 Feb; 195(2):74-7. PubMed ID: 7732190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reasons given by patients for "non-progression' in HIV infection.
    Troop M; Easterbrook P; Thornton S; Flynn R; Gazzard B; Catalan J
    AIDS Care; 1997 Apr; 9(2):133-42. PubMed ID: 9135629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
    Wintermeyer SM; Nahata MC; Brady MT; Sobol BJ; Venglarcik JS 3rd ; Baker RC; Hunkler JA; McOwen NM
    Pediatr AIDS HIV Infect; 1997 Apr; 8(2):120-6. PubMed ID: 11361778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
    Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
    AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
    Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
    Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children.
    Allen UD; King SM; Gomez MP; Lapointe N; Forbes JC; Thorne A; Kirby MA; Bowker J; Raboud J; Singer J; Mukwaya G; Tobin J; Read SE
    AIDS; 1998 Oct; 12(14):1785-91. PubMed ID: 9792379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
    Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
    Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.